FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TEL AVIV, Israel and AHMEDABAD, India, July 05, 2017 -- (NASDAQ:PAHC)
Phibro Animal Health Corporation and Zydus Cadila today announced their intention to enter into a long-term arrangement to license Phibro’s innovative poultry vaccine technologies and know-how to a new vaccine manufacturing facility to be built by Zydus Cadila to serve the fast growing poultry market in India.
Jack Bendheim, Chairman, President and Chief Executive Officer of Phibro, remarked, “We are proud of the more than 20-year partnership with Zydus Cadila serving the Indian animal health market and we view this as an exciting next step in our relationship.”
Speaking on the development Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group said, “Our endeavor has always been to enable access to innovative therapies across geographies and this agreement with Phibro will help bring innovations to the poultry market in India. The availability of new advanced poultry vaccines, which were until now being imported into India, adds a new dimension to the Make-in-India movement in the animal health segment.”
About Zydus Animal Health
With a strong presence in the livestock and poultry segments, Zydus Animal Health is India’s leading animal healthcare player and a market leader in various therapeutic segments which include antibacterials, NSAIDs, antimastitis, tonics and poultry vaccines amongst others in India. Zydus Animal Health has introduced the highest number of ‘First in India’ products, in keeping with its mission to provide innovative solutions that improve animal health and farm productivity.
About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. The group aspires to be a research-based pharmaceutical company by 2020.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, dairy, beef cattle and aquaculture. For further information, please visit www.pahc.com.
Contact: Phibro Animal Health Corporation Richard Johnson Chief Financial Officer +1-201-329-7300 or [email protected] Sujatha Rajesh Vice President – Corporate Communications Zydus Cadila +91-997-405-1180 [email protected]
